Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Greg G. Jones, Isabel Boned del Río, Sibel Sarı, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 68

Showing 26-50 of 68 citing articles:

LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis
Haiming Du, Senlin Hou, Lichao Zhang, et al.
Aging (2023) Vol. 15, Iss. 9, pp. 3759-3770
Open Access | Times Cited: 9
Synthetic lethal strategies for the development of cancer therapeutics
Natalie Ngoi, David Gallo, C. Sevillano, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 3
The leucine‐rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease
Hyein Jang, Payton D. Stevens, Tianyan Gao, et al.
FEBS Journal (2020) Vol. 288, Iss. 3, pp. 721-739
Open Access | Times Cited: 26
Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment
Bárbara Matos, John Howl, Cármen Jerónimo, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2680-2698
Open Access | Times Cited: 23
Developing SHP2-based combination therapy for KRAS-amplified cancer
Tianxia Li, Osamu Kikuchi, Jin Zhou, et al.
JCI Insight (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 7
Is the Proteome of Bronchoalveolar Lavage Extracellular Vesicles a Marker of Advanced Lung Cancer?
Ana Sofía Carvalho, Maria Carolina Strano Moraes, Chan Hyun Na, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3450-3450
Open Access | Times Cited: 20
CEN ‐tools: an integrative platform to identify the contexts of essential genes
Sumana Sharma, Cansu Dinçer, Paula Weidemüller, et al.
Molecular Systems Biology (2020) Vol. 16, Iss. 10
Open Access | Times Cited: 19
The Sag-Shoc2 axis regulates conversion of mPanINs to cystic lesions in Kras pancreatic tumor model
Mingjia Tan, Yu Chang, Xiaoqiang Liu, et al.
Cell Reports (2022) Vol. 41, Iss. 12, pp. 111837-111837
Open Access | Times Cited: 11
<p>Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway</p>
Haoyue Hu, Yanyang Liu, Songtao Tan, et al.
Cancer Management and Research (2020) Vol. Volume 12, pp. 3579-3587
Open Access | Times Cited: 17
SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells
Hideki Terai, Junko Hamamoto, Katsura Emoto, et al.
Molecular Cancer Research (2020) Vol. 19, Iss. 2, pp. 317-328
Open Access | Times Cited: 17
Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
Jennifer J. Lee, Vaibhav Jain, Ravi K. Amaravadi
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12402-12402
Open Access | Times Cited: 14
RAF1 deficiency causes a lethal syndrome that underscores RTK signaling during embryogenesis
Samantha Wong, Yu Xuan Tan, Abigail Loh, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 5
Open Access | Times Cited: 5
SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
Wenwen Geng, Meiling Cao, Ke Dong, et al.
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
Huiyu Li, Wei-liang Qi, Yuxiang Wang, et al.
Genes & Diseases (2021) Vol. 10, Iss. 2, pp. 403-414
Open Access | Times Cited: 10
Translating the Role of mTOR- and RAS-Associated Signalopathies in Autism Spectrum Disorder: Models, Mechanisms and Treatment
Verica Vasić, Mattson S. O. Jones, Denise Haslinger, et al.
Genes (2021) Vol. 12, Iss. 11, pp. 1746-1746
Open Access | Times Cited: 10
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
Marta Llauradó Fernández, E. Marielle Hijmans, Annemiek M.C. Gennissen, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 12, pp. 1862-1874
Open Access | Times Cited: 7
SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer
Wenwen Geng, Ke Dong, Qian Pu, et al.
Molecular Medicine Reports (2019)
Open Access | Times Cited: 10
Spotlight on Accessory Proteins: RTK-RAS-MAPK Modulators as New Therapeutic Targets
Silke Pudewell, Mohammad Reza Ahmadian
Biomolecules (2021) Vol. 11, Iss. 6, pp. 895-895
Open Access | Times Cited: 8
IKKα promotes lung adenocarcinoma growth through ERK signaling activation via DARPP-32-mediated inhibition of PP1 activity
Sk. Kayum Alam, Li Wang, Zhu Zhu, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 3
RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations
Daniel A. Bonsor, Dhirendra K. Simanshu
Annual Review of Cancer Biology (2023) Vol. 8, Iss. 1, pp. 97-113
Closed Access | Times Cited: 3
Identification of PIGU as the Hub Gene Associated with KRAS Mutation in Colorectal Cancer by Coexpression Analysis
Meng Zhang, Haizhou Wang, Haiou Li, et al.
DNA and Cell Biology (2020) Vol. 39, Iss. 9, pp. 1639-1648
Closed Access | Times Cited: 8
Structural insights into the role of SHOC2‐MRAS‐PP1C complex in RAF activation
Daniel A. Bonsor, Dhirendra K. Simanshu
FEBS Journal (2023) Vol. 290, Iss. 20, pp. 4852-4863
Open Access | Times Cited: 2
Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
Hannah R. Warren, Sarah J. Ross, Paul D. Smith, et al.
Biochemical Journal (2022) Vol. 479, Iss. 18, pp. 1985-1997
Open Access | Times Cited: 4
Single-domain antibodies for functional targeting of the signaling scaffold Shoc2
Hyein Jang, Patricia G. Wilson, Mary Sau, et al.
Molecular Immunology (2019) Vol. 118, pp. 110-116
Open Access | Times Cited: 5
SHOC2 scaffold protein modulates daunorubicin-induced cell death through p53 modulation in lymphoid leukemia cells
Vanessa S. Silveira, Kleiton Silva Borges, Verena Silva Santos, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 4

Scroll to top